Direct role for smooth muscle cell mineralocorticoid receptors in vascular remodeling: Novel mechanisms and clinical implications

Current Hypertension Reports

Volumn 16, Issue 5, 2014, Pages

  Koenig, Jenny B ^a   Jaffe, Iris Z ^a,b,c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

Aldosterone; Mineralocorticoid receptor; Smooth muscle cells; Vascular injury; Vascular remodeling

Indexed keywords

GALECTIN; GALECTIN 3; MINERALOCORTICOID RECEPTOR; PLACENTAL GROWTH FACTOR; RHO KINASE; VASCULOTROPIN RECEPTOR 1; MINERALOCORTICOID ANTAGONIST;

BLOOD VESSEL INJURY; HEART MUSCLE FIBROSIS; HUMAN; KNOCKOUT MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PHYSIOLOGICAL STRESS; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR DISEASE; VASCULAR REMODELLING; ANIMAL; CYTOLOGY; HYPERTENSION; METABOLISM; VASCULAR REMODELING; VASCULAR SYSTEM INJURIES;

ANIMALS; HUMANS; HYPERTENSION; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MYOCYTES, SMOOTH MUSCLE; RECEPTORS, MINERALOCORTICOID; VASCULAR REMODELING; VASCULAR SYSTEM INJURIES;

EID: 84899047476     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-014-0427-y     Document Type: Review

References (33)

1. Goel SA, Guo LW, Liu B, Kent KC. Mechanisms of postintervention arterial remodelling. Cardiovasc Res. 2012;96:363-71.
2. Rogerson FM, Fuller PJ. Mineralocorticoid action. Steroids. 2000;65:61-73. (Pubitemid 30009768)
3. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-17. (Pubitemid 29407370)
4. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-21. (Pubitemid 36384098)
5. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 1831-1838;2003:108.
6. Zannad F, Mcmurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21.
7. Ivanes F, Susen S, Mouquet F, Pigny P, Cuilleret F, Sautiere K, et al. Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure. Eur Heart J. 2012;33:191-202.
8. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243-8. (Pubitemid 40523144)
9. Ehsan A, McGraw AP, Aronovitz M, Galayda C, Conte MS, Karas RH, et al. Mineralocorticoid receptor antagonism inhibits vein graft remodeling in mice. J Thorac Cardiovasc Surg. 2012;145:1642-9.
10. Jaffe IZ, Newfell BG, Aronovitz M, Mohammad NN, McGraw AP, Perreault RE, et al. Placental growth factor mediates aldosterone-dependent vascular injury in mice. J Clin Invest. 2010;120:3891-900.
11. Van Belle E, Bauters C, Wernert N, Hamon M, McFadden EP, Racadot A, et al. Neointimal thickening after balloon denudation is enhanced by aldosterone and inhibited by spironolactone, and aldosterone antagonist. Cardiovasc Res. 1995;29(1):27-32.
12. Ward MR, Kanellakis P, Ramsey D, Funder J, Bobik A. Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation. 2001;104(4):467-72. (Pubitemid 32678279)
13. Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res. 2005;96(6):643-50. (Pubitemid 40478331)
14. Jaffe IZ, Tintut Y, Newfell BG, Demer LL, Mendelsohn ME. Mineralocorticoid receptor activation promotes vascular cell calcification. Arterioscler Thromb Vasc Biol. 2007;27(4):799-805. (Pubitemid 46606709)
15. Newfell BG, Iyer LK, Mohammad NN, McGraw AP, Ehsan A, Rosano G, et al. Aldosterone Regulates Vascular Gene Transcription via Oxidative Stress-Dependent And -Independent Pathways. Arterioscler Thromb Vasc Biol. 1871-1880;2011:31.
16. Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, Horiuchi M. Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res. 2005;97(5):434-42. (Pubitemid 41298173)
17. Xiao F, Puddefoot JR, Vinson GP. Aldosterone mediates angiotensin II-stimulated rat vascular smooth muscle cell proliferation. J Endocrinol. 2000;165:533-6. (Pubitemid 30341103)
18. •• McCurley A, Pires PW, Bender SB, Aronovitz M, Zhao MJ, Metzger D, et al. Direct Regulation of Blood Pressure by Smooth Muscle Cell Mineralocorticoid Receptors. Nat Med. 2012;18:1429-33. This paper describes the phenotype of the inducible SMC-MR-KO mouse which has decreased blood pressure, vascular tone, and angiotensin II-mediated oxidative stress with aging. This is a novel and important model for studying the specific role of SMC-MR in aldosterone-mediated vascular remodeling.
19. •• Pruthi D, McCurley A, Aronovitz M, Galayda C, Karumanchi SA, Jaffe IZ: Aldosterone Promotes Vascular Remodeling by Direct Effects on Smooth Muscle Cell Mineralocorticoid Receptors. Arterioscler Thromb Vasc Biol. 2014;34:355-46. This paper demonstrates that SMC-MR is necessary for aldosterone-induced vascular remodeling and for injury-induced vascular fibrosis, even with physiological levels of aldosterone. This study also implicates SMC-MR regulation of PGF and VEGFR1 in the mechanism of aldosterone-induced vascular remodeling in vivo.
20. •• Galmiche G, Pizard A, Gueret A, Moghrabi SE, Ouvrard-Pascaud A, Berger S, Challande P, Jaffe IZ, Labat C, Lacolley P, Jaisser F: Smooth Muscle Cell Mineralocorticoid Receptors Are Mandatory for Aldosterone-Salt to Induce Vascular Stiffness. Hypertension. 2014;63:520-6. This paper shows that SMC-MR is necessary for the development of vascular stiffness in response to hypertension in the uninephrectomy/aldosterone/salt hypertension model and suggests that the mechanism involves increased expression of the integrin alpha-5 subunit.
21. Duprez DA. Arterial stiffness/elasticity in the contribution to progression of heart failure. Heart Fail Clin. 2012;8:135-41.
22. Marti CN, Gheorghiade M, Kalogeropoulos AP, Georgiopoulou VV, Quyyumi AA, Butler J. Endothelial dysfunction, arterial stiffness, and heart failure. J Am Coll Cardiol. 2012;60:1455-69.
23. McCurley A, Jaffe IZ. Mineralocorticoid Receptors in Vascular Function and Disease. Mol Cell Endocrinol. 2011;350:256-65.
24. Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res. 2006;98:322-34.
25. Miyata K, Hitomi H, Guo P, Zhang GX, Kimura S, Kiyomoto H, et al. Possible involvement of Rho-kinase in aldosterone-induced vascular smooth muscle cell remodeling. Hypertens Res. 2008;31:1407-13.
26. •• Montezano AC, Callera GE, Yogi A, He Y, Tostes RC, He G, et al. Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways. Arterioscler Thromb Vasc Biol. 2008;28(8):1511-8. This paper proposes a mechanism for vascular remodeling involving the synergistic activation of a c-Src-dependent, redox-sensitive, Rho-kinase pathway by aldosterone/SMC-MR and angiotensin-II in SMCs.
27. Fujimura N, Noma K, Hata T, Soga J, Hidaka T, Idei N, et al. Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension. Clin Pharmacol Ther. 2012;91:289-97.
28. de Boer RA, Edelmann F, Cohen-Solal A, Mamas MA, Maisel A, Pieske B. Galectin-3 in heart failure with preserved ejection fraction. Eur J Heart Fail. 2014;15:1095-101.
29. •• Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, de Boer RA, et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol. 2013;33:67-75. This paper identifies galectin-3 as a SMC-MR-regulated gene and demonstrates that hypertension-induced vascular remodeling occurs via -MR-mediated upregulation of galectin-3, resulting in increased vascular collagen-I production and fibrosis.
30. Felker GM, Fiuzat M, Shaw LK, Clare R, Whellan DJ, Bettari L, et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail. 2012;5:72-8.
31. Fiuzat M, Schulte PJ, Felker GM, Ahmad T, Neely M, Adams KF, Donahue MP, Kraus WE, Pina IL, Whellan DL, O'Connor CM: Relationship between Galectin-3 Levels and Mineralocorticoid Receptor Antagonist Use in Heart Failure: Analysis from the HF-ACTION Study. J Card Fail. 2014;20(1):38-44.
32. McGraw AP, McCurley A, Preston IR, Jaffe IZ. Mineralocorticoid receptors in vascular disease: connecting molecular pathways to clinical implications. Curr Atheroscler Rep. 2013;15:340.
33. Preston IR, Sagliani KD, Warburton RR, Hill NS, Fanburg BL, Jaffe IZ. Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2013;304:L678-88.